BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug

BioMarin positive factors rights to a Fabry illness enzyme substitute remedy with potential dosing benefits over merchandise from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset might attain sufferers ineligible for the Fabry drug that got here with its Amicus Therapeutics acquisition earlier this yr.

The submit BioMarin Expands Once more in Enzyme Alternative, Paying $70M for Lengthy-Performing Fabry Drug appeared first on MedCity Information.

Source link